drugset / Trial / NCT05043077

Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening

NCT05043077 ↗

RandomizedCrossoverQuadruple-blindScreening

Summary

The purpose is to test the hypothesis that microdrop instillation of combined phenylephrine 1.67% and tropicamide 0.33% eyedrops causes at least equal mydriasis compared with standard drop instillation of the same mydriatic regimen, which constitutes routine care for pupil dilation during retinopathy of prematurity (ROP) screening in our neonatal intensive care unit. Comparison, also, will be made to the subsequent adverse events and the drug concentration in peripheral blood samples.

Timeline

Start
2021-09-07
Primary completion
2023-01-20
Completion
2023-01-23

Outcome

Met primary endpoint

paper Microdrops proved to be superior regarding mydriatic efficacy at 45 minutes (mean difference, 0.12; Bonferroni-corrected 95% CI, 0.01 to 0.23; P = .008) PMID 39724200 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Phenylephrine Small molecule 1.67 % Topical
Subject tropicamide Small molecule 0.33 % Topical